임상시험 지원 소프트웨어 솔루션 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

Cloud and web-based deployment represented 68.24% of delivery mode demand in 2025, and that leads to this being the clearest structural choice inside the clinical trial software market. It is also expected to be the fastest-growing delivery mode, with a projected 15.37% CAGR through 2031, so the largest segment is still widening its lead.

According to Mordor Intelligence, the clinical trials support software solutions market was valued at USD 11.52 billion in 2025 and is projected to be valued at USD 12.99 billion in 2026. This report is Segmented by Product Type (Clinical Analytics Platforms and More), Delivery Mode (On-Premises and More), Clinical Trial Phase (Phase I and More), Trial Model (Hybrid Trial Solutions and More), Therapeutic Area (Oncology and More), End-User (Hospitals and Healthcare Providers, and More), and Geography (North America, Europe, and More). Forecasts in Value (USD).

Global Clinical Trials Support Software Solutions Market Trends and Insights

Rising Complexity of Multinational Multi-Protocol Trial Operations

The clinical trials support software solutions market is gaining support from the rising operational complexity of multinational studies that involve more sites, more countries, and more parallel workflows. Large programs now require tight coordination across data capture, trial management, document control, safety reporting, and oversight functions, which makes fragmented system setups harder to manage. This pressure is strongest in later-stage and oncology-heavy programs where protocol changes, regional operating differences, and dense reporting requirements create repeated workflow adjustments. Unified platforms are becoming more attractive in this setting because they allow teams to manage changes inside one operating structure rather than reconciling several point tools after each update. That shift improves consistency in trial execution and makes platform standardization more valuable for sponsors with large global portfolios. It also favors vendors that can support repeatable study builds, shared metadata, and cross-study reuse in regulated environments.

Shift from Point Solutions to Unified Trial Operating Systems

The clinical trials support software solutions market is also being pushed by a clear move away from separate tools for EDC, CTMS, eTMF, eConsent, and related functions. Sponsors want fewer system handoffs because each extra interface can add reconciliation work, validation effort, and operational delay. The move toward a unified operating model is gaining force because regulators are asking for better visibility into how oversight actions, protocol execution, and data handling are documented across the full study lifecycle. In 2025, the M11 technical specification advanced formal structured protocol expectations, which supports the broader push toward more consistent and digital study design workflows. Veeva's 2026 report also shows that clinical data organizations are prioritizing simplification and standardization, which fits the same direction of travel in the clinical trials support software solutions market. As a result, vendors with native workflows across core modules are in a stronger position than vendors that depend mainly on stitched integrations.

Fragmented Legacy Data Models Across Sponsor, CRO, and Site Systems

The clinical trials support software solutions market still faces resistance from legacy data structures that have been built over long development histories. Large sponsors often run a mix of old validated systems and newer cloud tools, and that makes full migration slower than the demand story alone would suggest. Every change to a regulated system can trigger validation work, documentation reviews, and operational retraining, which raises the cost of moving too quickly. This is especially difficult when multiple systems feed one trial program and each one handles study logic, reporting, or document control in a slightly different way. As a result, many organizations are choosing phased modernization instead of broad replacement programs. That slows adoption speed in the clinical trials support software solutions market even when the strategic case for consolidation is already clear.

Other drivers and restraints analyzed in the detailed report include:

1. Sponsor Demand for Real-Time Site, Patient, and Supply Visibility
2. Compliance-Driven Digitization of Audit Trails and Inspection Readiness
3. Site-Level Software Overload Reducing User Adherence

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Electronic data capture (EDC) & clinical data management systems held 34.76% of product type demand in 2025, which kept them at the center of the clinical trials support software solutions market because data capture and clinical data handling remain essential in every study. These systems sit close to the core record of trial activity, so they are often the first software decision in a new program. Their position is strengthened by the fact that later functions such as monitoring, documentation, and analytics still depend on clean and timely source data flow from the capture layer. In practical terms, sponsors and CROs continue to treat EDC and CDMS as foundational even when they are broadening spend into adjacent modules. That is why the leading share stayed with this category despite the growth of more specialized functions across the clinical trial software market.

The fastest-growing product type is clinical trial management systems (CTMS), which is projected to expand at a 16.84% CAGR through 2031. That pace reflects a shift in how trial teams use CTMS, from a passive record-keeping tool toward a live coordination system for milestones, oversight, and operational visibility. RTSM still retains a distinct position because adaptive and multi-arm studies require specialized allocation and supply logic. Analytics and data integration layers are also becoming more valuable because they connect operational systems with external feeds, including wearables and health record inputs, into one decision environment. That means product competition is now shaped as much by integration depth as by module-specific features.

Cloud delivery fits the needs of multinational trials because it supports easier scaling, faster software updates, and broader access across sponsor, CRO, and site teams. It also supports more consistent rollout of new workflows across countries without the same infrastructure burden associated with local installations. For many buyers, deployment is no longer a simple IT preference. It now affects how quickly a platform can support compliance changes, global study expansion, and connected oversight.

On-premises models still exist, especially in large legacy environments or places with strict data residency expectations. Even so, these deployments are increasingly moving toward hybrid or private cloud structures instead of full stand-alone systems. That suggests the real question is not whether cloud will lead, but how fast holdout environments can transition without disrupting validated operations. The delivery pattern also changes the vendor landscape because cloud-native design can make deployment simpler for mid-sized sponsors and growth-stage biopharma companies.

Complete Report Scope:

• By Product Type
  • Electronic Data Capture and Clinical Data Management Systems
  • Clinical Trial Management Systems
  • Clinical Analytics Platforms
  • Randomization and Trial Supply Management Solutions
  • Electronic Clinical Outcome Assessment Solutions
  • Electronic Trial Master File Solutions
  • Regulatory Information Management Solutions
  • Clinical Data Integration Platforms
  • Risk Based Quality Management Solutions
  • Payments and Investigator Payments Solutions
  • Other Product Types
• By Delivery Mode
  • Cloud and Web-Based
  • On-Premises
• By Clinical Trial Phase
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
• By Trial Model
  • Traditional Site-Based Trial Solutions
  • Hybrid Trial Solutions
  • Decentralized Clinical Trial Solutions
• By Therapeutic Area
  • Oncology
  • Central Nervous System and Neurology
  • Cardiovascular and Metabolic Diseases
  • Rare Diseases
  • Infectious Diseases
  • Other Therapeutic Diseases
• By End-User
  • Contract Research Organizations (CROs)
  • Pharmaceutical and Biotechnological Companies
  • Hospitals and Healthcare Providers
  • Other End-Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 40.18% of the clinical trials support software solutions market size in 2025, which made it the leading regional segment. The United States remains the main anchor because it has a high concentration of industry-sponsored Phase II and Phase III studies and a regulatory environment that is actively shaping digital trial practice. The FDA's 2024 decentralized trial guidance and its 2025 Dataset-JSON proposal have given sponsors and vendors a clearer operating path for digital workflows and submission-ready data handling. Canada and Mexico support regional trial activity as well, with Mexico retaining a role in cost-sensitive late-stage enrollment programs.

Europe remained the second-largest region in the clinical trials support software solutions market and is moving through an important regulatory transition. The EU Clinical Trials Regulation framework and CTIS standardization have pushed sponsors and CROs toward more consistent submission and workflow practices across member states. FAST-EU, which moved forward in late 2025 and early 2026, adds to that direction by aiming to streamline multinational approvals within the region. The European Health Data Space also adds a longer-term driver because wider cross-border health data access for research can increase the need for stronger integration and data governance tools.

Asia-Pacific is forecasted to grow at a 17.82% CAGR through 2031, making it the fastest-growing regional segment in the clinical trial software market. China and Japan are the main anchor markets, while India and South Korea are expanding as clinical hubs in the regional mix. China's revised GCP framework, issued in June 2026 and effective from September 2026, strengthens the region's data governance direction and raises the value of validated software controls in ongoing and future studies. That change supports stronger demand for electronic audit trails, metadata handling, and broader computerized system discipline. South America and the Middle East and Africa remain smaller in absolute size, but they continue to gain attention as sponsors seek wider patient diversity and faster enrollment across more geographies. Within those regions, Brazil, South Africa, and GCC countries remain the most visible activity centers. Taken together, the regional picture shows a clinical trials support software solutions market led by North America in current scale, supported by Europe's regulatory alignment, and accelerated by Asia-Pacific's faster expansion.

1. 4G Clinical
2. Advarra
3. Castor
4. Clario
5. Clinion
6. Dassault Systemes
7. eClinical Solutions
8. Ennov
9. Fountayn
10. ICON
11. IQVIA
12. MaxisIT
13. Medidata
14. OpenClinica, LLC
15. Oracle
16. Saama
17. Signant Health
18. Suvoda LLC
19. Thermo Fisher Scientific
20. Veeva Systems

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Complexity of Multinational, Multi-Protocol Trial Operations
  • 4.2.2 Shift from Point Solutions to Unified Trial Operating Systems
  • 4.2.3 Sponsor Demand for Real-Time Site, Patient, and Supply Visibility
  • 4.2.4 Compliance-Driven Digitization of Audit Trails and Inspection Readiness
  • 4.2.5 Direct Integration Pressure from Decentralized Trial Workflows
  • 4.2.6 Clinical Finance and Payments Automation Becoming a Trial Retention Lever
• 4.3 Market Restraints
  • 4.3.1 Fragmented Legacy Data Models Across Sponsor, CRO, and Site Systems
  • 4.3.2 Validation, Configuration, and Change-Control Burden for Regulated Deployments
  • 4.3.3 Site-Level Software Overload Reducing User Adherence
  • 4.3.4 Interoperability Gaps with eSource, EHR, and Safety Stacks
• 4.4 Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Electronic Data Capture and Clinical Data Management Systems
  • 5.1.2 Clinical Trial Management Systems
  • 5.1.3 Clinical Analytics Platforms
  • 5.1.4 Randomization and Trial Supply Management Solutions
  • 5.1.5 Electronic Clinical Outcome Assessment Solutions
  • 5.1.6 Electronic Trial Master File Solutions
  • 5.1.7 Regulatory Information Management Solutions
  • 5.1.8 Clinical Data Integration Platforms
  • 5.1.9 Risk Based Quality Management Solutions
  • 5.1.10 Payments and Investigator Payments Solutions
  • 5.1.11 Other Product Types
• 5.2 By Delivery Mode
  • 5.2.1 Cloud and Web-Based
  • 5.2.2 On-Premises
• 5.3 By Clinical Trial Phase
  • 5.3.1 Phase I
  • 5.3.2 Phase II
  • 5.3.3 Phase III
  • 5.3.4 Phase IV
• 5.4 By Trial Model
  • 5.4.1 Traditional Site-Based Trial Solutions
  • 5.4.2 Hybrid Trial Solutions
  • 5.4.3 Decentralized Clinical Trial Solutions
• 5.5 By Therapeutic Area
  • 5.5.1 Oncology
  • 5.5.2 Central Nervous System and Neurology
  • 5.5.3 Cardiovascular and Metabolic Diseases
  • 5.5.4 Rare Diseases
  • 5.5.5 Infectious Diseases
  • 5.5.6 Other Therapeutic Diseases
• 5.6 By End-User
  • 5.6.1 Contract Research Organizations (CROs)
  • 5.6.2 Pharmaceutical and Biotechnological Companies
  • 5.6.3 Hospitals and Healthcare Providers
  • 5.6.4 Other End-Users
• 5.7 By Geography
  • 5.7.1 North America
    • 5.7.1.1 United States
    • 5.7.1.2 Canada
    • 5.7.1.3 Mexico
  • 5.7.2 Europe
    • 5.7.2.1 Germany
    • 5.7.2.2 United Kingdom
    • 5.7.2.3 France
    • 5.7.2.4 Italy
    • 5.7.2.5 Spain
    • 5.7.2.6 Rest of Europe
  • 5.7.3 Asia-Pacific
    • 5.7.3.1 China
    • 5.7.3.2 Japan
    • 5.7.3.3 India
    • 5.7.3.4 Australia
    • 5.7.3.5 South Korea
    • 5.7.3.6 Rest of Asia-Pacific
  • 5.7.4 Middle East and Africa
    • 5.7.4.1 GCC
    • 5.7.4.2 South Africa
    • 5.7.4.3 Rest of Middle East and Africa
  • 5.7.5 South America
    • 5.7.5.1 Brazil
    • 5.7.5.2 Argentina
    • 5.7.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)
  • 6.3.1 4G Clinical
  • 6.3.2 Advarra
  • 6.3.3 Castor
  • 6.3.4 Clario
  • 6.3.5 Clinion
  • 6.3.6 Dassault Systemes
  • 6.3.7 eClinical Solutions LLC
  • 6.3.8 Ennov
  • 6.3.9 Fountayn
  • 6.3.10 ICON Plc
  • 6.3.11 IQVIA
  • 6.3.12 MaxisIT
  • 6.3.13 Medidata
  • 6.3.14 OpenClinica, LLC
  • 6.3.15 Oracle
  • 6.3.16 Saama
  • 6.3.17 Signant Health
  • 6.3.18 Suvoda LLC
  • 6.3.19 Thermo Fisher Scientific Inc.
  • 6.3.20 Veeva Systems

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment